Meletios Therapeutics

We are developing a new generation of broad-spectrum antiviral #treatments to address the existing and emerging viral diseases The €5.2 M #funding will allow us to start the clinical demonstration of efficacy of our lead candidate MLT103 More info 👉 bit.ly/meletios

Meletios Therapeutics, selected by the European Commission through its EIC Accelerator program receives a 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝗼𝗳 𝟱.𝟮 𝗠€ More info here 👉 bit.ly/meletios #innovation #health #financing #EICAccelerator

Meletios Therapeutics was selected as one of the 𝟳𝟱 𝗮𝘄𝗮𝗿𝗱𝗲𝗱 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 of the European Commission's 𝗘𝗜𝗖 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗼𝗿 program, out of more than 1000 applicants #innovation #health #biotech #EICAccelerator

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? In 2021, the #FDA approved 4 novel small molecule drugs for infectious #diseases, and 2 of them are against viruses: HIV-1 and (post-transplant) cytomegalovirus #virus #drugs #HIV #DidUKnow

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? Dengue #virus transmission occur when mosquito bite Dengue virus infection modifies blood-feeding behavior of mosquitoes which bite more often to get the same amount of blood as uninfected mosquitoes ➡️ increased rate of infection #Dengue #DidUKnow

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? The first antiviral treatment, idoxuridine, was discovered less than 60 years ago in 1963 Initially developed as an anticancer, idoxuridine is mainly used topically to treat herpes simplex keratitis meletiostx.com #DidUKnow #treatment #virus

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? #Dengue spread dramatically during World War II, especially to Southeast Asia and the Pacific Islands, due to troops and equipment movement of that enabled the transport of the #virus and its mosquito vector 👉 meletiostx.com

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? More than 95% of adults worldwide are asymptomatically infected with Epstein-Barr #Virus Infection during infancy is not associated with obvious symptoms, whereas infection during/after the teenage years frequently causes infectious #mononucleosis

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? In May 2015, the World Health Organization @WHO published the best practices for the naming of human infectious diseases More infos 👉 bit.ly/3mm4cen #WorldHealthOrganization #WHO #diseases #virus #DidUKnow

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? #SARSCoV2 has experienced roughly the same amount of mutational evolutionary change during the #pandemic (proportional to genome size), as humans have since Homo habilis first walked the Earth about 2.5M years ago #COVID19 #virus #DidUKnow

Meletios Therapeutics just registered for BIO-Europe-SPRING (Digital #event) on March 28-31, 2022 🗓️. Join & meet us! #BIOEuropeSpring #biotech

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? #Chikungunya owes its origin to Kungunyala, a word from the Makoude language of Tanzania meaning “that which bends up” ➡️ meletiostx.com #virus #DidUKnow

🦠 Looking for #virology solutions? Explore 5 top #biotech #startups that'll help you step up your game with rapid detection test, phage-based biocontrol, #anti-viral molecules, & more 👉 startus-insights.com/innovators-gui… ft. @OncoMyx @meletios_tx @bluephageWATER #healthtech #innovation

Watch this #video of Catherine Martre, CEO of Meletios Therapeutics, and learn more about how the licences agreement fits into Meletios' strategy against emerging viral diseases 👇

𝑾𝒉𝒂𝒕 𝒂𝒓𝒆 𝑫𝑽𝑮𝒔 ? Marco Vignuzzi answers us in this #video and details their therapeutic potential 👇

Marco Vignuzzi provides details on the license agreement between Meletios Therapeutics and the Institut Pasteur - @institutpasteur - in #video 👇

𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? Infection with #herpes, can be due to either herpes virus type 1 (HSV-1) or herpes virus type 2 (HSV-2). In 2016, WHO estimated that 3.7 billion people <50 years old had HSV-1 #infection corresponding to 50% of the worldwide population #virus #DidUKnow

Marco Vignuzzi presents the Viral Populations and Pathogenesis Unit of the Institut Pasteur in #video 👇

[VIDEO] Watch this #video #interview 📽️ with Marco Vignuzzi, Head of the Viral Populations and Pathogenesis Unit at @institutpasteur & Catherine Martre, CEO of @meletios_tx vimeo.com/683705659